Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Number,Of,Cigarettes,Isolated,Tobacco,Danger,Close,Up,Quit,Smoking

Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, positioning the company for a high-stakes commercial launch in 2026.

In a vote of confidence for the late-stage specialty pharmaceutical company’s pipeline with a focus on smoking health and nicotine dependence, HC Wainwright has initiated coverage on Achieve Life Sciences with a Buy rating and a $12 price forecast.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.